| Literature DB >> 22267841 |
A P A van Montfoort1, L L P Hanssen, P de Sutter, S Viville, J P M Geraedts, P de Boer.
Abstract
BACKGROUND: The subject of epigenetic risk of assisted reproduction treatment (ART), initiated by reports on an increase of children with the Beckwith-Wiedemann imprinting disorder, is very topical. Hence, there is a growing literature, including mouse studies.Entities:
Mesh:
Year: 2012 PMID: 22267841 PMCID: PMC3282574 DOI: 10.1093/humupd/dmr047
Source DB: PubMed Journal: Hum Reprod Update ISSN: 1355-4786 Impact factor: 15.610
Figure 1Characteristics of a chromatin domain. Schematic representation of the covalent and structural features that define a certain chromatin domain. Different contributing factors are highlighted in shaded boxes. The dashed line represents a separation between two adjacent domains. Figure from Margueron and Reinberg (2010).
Figure 4Epigenetic state of the imprinted Igf2/H19 domain on the maternal and paternal genome. On the paternal chromosome, the H19 gene and the adjacent DMR are methylated preventing H19 expression and the binding of the insulator CTCF, thus allowing enhancers access to the Igf2 gene promoting its expression. In the absence of DMR methylation on the maternal chromosome, bound CTCF prevents enhancer activity reaching Igf2, effectively silencing the gene. Instead, enhancer activity is limited to the unmethylated H19 gene resulting in its expression on the maternally contributed chromosome. Figure from Reik and Murrell (2000).
Figure 2Imprinting in the germline. Erasure, establishment and maintenance of methylation imprints at imprinting control regions during germ cell and embryonic development. Imprinting control regions (IC1) and IC2 are shown as examples. Grey indicates modification and white indicates no modification at the corresponding alleles. Parental chromosomes are marked according to their sex in blue (male) or red (female). The reading in the developing embryo is indicated by arrows. Figure from Reik and Walter (2001).
Figure 3Chronology of mouse germ cell development and the main epigenetic events that occur. PGCs first emerge at embryonic Day 7.25 (E7.25) after which they migrate to the gonad where they enter the process of sex differentiation and eventually develop into full-grown gametes. Green bars indicate the developmental stage and yellow bars indicate the epigenetic processes occurring at these points in the germ line. MSCI stands for meiotic sex chromosome inactivation. Figure from Sasaki and Matsui (2008).
Figure 5(A) Methylation reprogramming in the germ line. PGCs in the mouse become demethylated early in development, between E7.5 and E13.5. Remethylation begins in prospermatogonia in male germ cells, and after birth in growing oocytes. (B) Methylation reprogramming in preimplantation embryos. The paternal genome (blue) is demethylated by an active mechanism immediately after fertilization. The maternal genome (red) is demethylated by a passive mechanism. Both are remethylated around the time of implantation to different extents in embryonic (EM) and extraembryonic (EX) lineages. Methylated imprinted genes and some repeat sequences (dashed line) do not become demethylated. Unmethylated imprinted genes (dashed line) do not become methylated. Figure from Reik ).
Survey of the mouse experiments aimed at testing imprinting and physiological parameters after ART.
| Reference | Genotype | Conditions | Readouts | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Superov | Superov | Superov IVF + cleavage | ET | Media comparison | Blastocyst gDMR methyl | Blastocyst Impr expr | Mid gest Embryo gDMR methyl | Mid gest Embryo Impr expr | Mid gest Placenta gDMR methyl | Mid gest Placenta Impr expr | |||
| B6(CAST7) | x | x | x | x | x | ||||||||
| B6(CAST7) | x | x | x | ||||||||||
| B6(CAST7) | x | x | x | x | x | ||||||||
| B6(CAST7) | x | x | x | x | x | x | x | x | x | x | |||
| B6CBA F1 | x | x | x | x | |||||||||
| B6CBA F1 x F1 | x | x | x | x | x | x | x | ||||||
| B6CBA F1 x F1 | x | x | x | x | x | x | x | x | x | ||||
| B6CBA F1 x F1 | x | x | x | a | |||||||||
| B6(CAST7) | x | x | x | x | x | x | x | x | |||||
| CD1 x B6(CAST7) | x | x | x | x | x | x | x | ||||||
| B6 x Spretus | x | x | x | ||||||||||
| FVB/N x B6 Avy/a | x | x | x | Phenotype epiallele | |||||||||
| B6CBA F1 x 129/Rr Axin1fu | x | x | x | Phenotype epiallele | |||||||||
| 129Sv x B6 | xb | x | x | Behavioural testing | |||||||||
| B6CBA F1 | x | x | x | Behavioural testing | |||||||||
| CBAB6 F1 x MF1 | x | x | x | Blood pressure, serum angiotensin converting enzyme, hepatic phosphoenolpyruvate carboxykinase | |||||||||
| B6C3 F1 | x | xc | x | Glucose parameters | |||||||||
Superov, superovulation; ET, embryo transfer; gDMR, germline differentially methylated region (DMR); Impr expr, Imprinted expression; Mid gest, mid gestation.
aTranscriptome analysis.
bIn vivo fertilization was followed by in vivo and in vitro development.
cCulture to the 2-cell stage.
Reports on the incidence of imprinting disorders after human IVF.
| Reference | Type of study | N cases | % IVF in cases | % IVF in ref | Estimated risk | Type of IVF | Molecular defect |
|---|---|---|---|---|---|---|---|
| Beckwith–Wiedemann syndrome | |||||||
| | Case series | 65 | 4.6 | 0.76 | 6.1 | IVF and ICSI | 5/6 LOM KCNQ1OT1 gDMRc |
| 1/6 GOM H19 DMR | |||||||
| 1/6 no imprint defect | |||||||
| | Case series | 149 | 4.0 | 0.997 | 4.0* | IVF ( | 2/6 LOM KCNQ1OT1 gDMR |
| 4/6 not analysed | |||||||
| | Case series | 149 | 4.0 | 1.3 | 3.1* | IVF ( | 6/6 LOM KCNQ1OT1 gDMR |
| | Case control | 37 | 10.8 | 0.67 | 16.1* | IVF ( | 3/4 LOM KCNQ1OT1 gDMR |
| 1/4 not analysed | |||||||
| | Case series | 341 | 5.6a | – | IVF ( | NA | |
| | Survey | 209 | 2.9–7.6b | 0.8 | 3.6–9.5b* | IVF ( | 6/6 LOM KCNQ1OT1 gDMR |
| | Survey | 71 | 5.6 | 0.92 | 6.1* | IVF ( | 4/4 LOM KCNQ1OT1 gDMR |
| Angelman Syndrome | |||||||
| | Case series | 2 | – | – | – | ICSI ( | 2/2 LOM SNRPN |
| | Case report | 1 | – | – | – | ICSI ( | 1/1 LOM SNRPN |
| | Survey | 79 | 3.8 | – | – | ICSI ( | 1/3 LOM SNRPN |
| 2/3 maternal deletion 15q11 | |||||||
| | Survey | 75 | 0 | 0.8 | – | – | – |
| | Survey | 63 | 0 | 0.92 | – | – | – |
LOM, loss of methylation; GOM, gain of methylation; –, not analysed.
aAll 19 ART cases are included, 10 after IVF (and ICSI), 2 after hormonal stimulation and insemination and 7 for which no data on type of ART were available.
bRange takes into account the large number of lost to follow-up by assuming that all non-responders conceived naturally.
cSix ART- Beckwith–Wiedemann syndrome cases were identified in a database. Three patients were from before 2001, when use of ART was not systematically assessed. This period was excluded from the risk assessment.
*Risk is significantly increased in IVF compared with non-IVF pregnancies.
DNA CpG methylation in human oocytes at different stages of development with and without ovarian stimulation and IVM.
| Reference | gDMR | Methylation | No ovarian stimulation | Ovarian stimulation, in vivo maturation | Ovarian stimulation, IVM of GV | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary follicle | Pre-antral follicle | Antral follicle | GV | MI | MII | Arrested GV | Arrested MI | MII | |||
| MEST | M | 50.0 | 57.0 | 91.6 | 55.6 (5/9) | 71.4 (5/7) | |||||
| PLAGL1 | M | 40.0 | 10.4 | 83.3 | |||||||
| KCNQ1OT1 | M | 55.5 | 66.6 | 87.5 | |||||||
| KCNQ1OT1 | M | 100 (6/6) | 83.3 (5/6) | 100c (4/4) | |||||||
| KCNQ1OT1 | M | 67.8 (GV)a | 62.5 | 66.7 | 89.5 | 61.2 | 65.2 | 78.3 | |||
| 70.3 (MI)a | |||||||||||
| SNRPN | M | 100 (7/7) | 100 (3/3) | 100c (3/3) | |||||||
| SNRPN | M | 0b | |||||||||
| NDN | M | 33.3b | |||||||||
| H19 | P | 28.2 | 33.4 | 12.5 | 0 (0/3) | 66.7 (2/3) | |||||
| H19 | P | 0 (0/5) | 24.3 | 13.8 | 16.7 | ||||||
| DLK1 | P | 0 (0/4) | 0 (0/6) | 0c (0/6) | |||||||
Methylation is depicted as the percentage of methylated alleles (greater-than two-third of DMR is methylated) of the total number of alleles analysed.
M, maternal; P, paternal.
If known, the number of methylated oocytes and the total number of oocytes are put in parentheses.
aGV and MI are obtained from non-stimulated patients with polycystic ovaries and after culture arrested in GV and MI.
bUnfertilized oocytes.
cMII obtained after culture of both GV and MI.
DNA CpG methylation studies on human spermatozoa from normal probands and subfertile patients.
| Reference | Conditions analysed | DMR | Methylation (M/P) | Technique | ART outcome analysed | ||||
|---|---|---|---|---|---|---|---|---|---|
| Normal | Concentration | Motility | Morphology | Other | |||||
| + | IG-DMR | P | Bisulphite sequencing | ||||||
| + | SNRPN | M | Bisulphite sequencing | ||||||
| + | KCNQ1OT1 | M | Bisulphite sequencing | ||||||
| + | Spermatids, Testicular (fetal) spermatogonia and spermatocytes | H19 MEST | P M | Bisulphite sequencing | |||||
| + | + | H19 MEST | P M | Bisulphite sequencing | |||||
| + | + | H19 MEST LINE1 | P M Global | Bisulphite sequencing | |||||
| + | + | H19 IG-DMR MEST KCNQ1OT1 PLAGL1 PEG3 SNRPN LINE1 Alu | P P M M M M M Global Global | Bisulphite sequencing + COBRA | + (1 child) | ||||
| + | + | ZDBF2 H19 IG-DMR MEST KCNQ1OT1 PEG3 SNRPN PLAGL1 | P P P M M M M M | Bisulphite polymerase chain reaction Luminex, bisulphite sequencing and COBRA | |||||
| + | + | Protamine replacement defect | H19 KCNQ1OT1 MEST SNRPN PLAGL1 IGF2 PEG3 | P M M M M M M | Bisulphite sequencing | ||||
| + | + | + | + | H19 MEST | P M | Bisulphite sequencing | |||
| + | + | + | + | Overall | global | Immunostaining | |||
| + | + | + | + | 37 regions 1421 regions | – – | MethyLight Illumina array | |||
| + | + | OAT | H19-CTCF3 H19 CTCF6 IGF2-DMR0 IGF2-DMR2 LINE1 | P P P P Global | Pyrosequencing | + (fertilization rate, cleavage and fragmentation) | |||
| + | OAT | DAZL DAZ | M+P M+P | Bisulphite sequencing | |||||
| El | + | OAT | H19 IG-DMR MEST KCNQ1OT1 PEG3 SNRPN NESPAS LINE1 | P P M M M M M Global | Pyrosequencing | + (Fertilization rate, pregnancy rate, live birth rate, abortion rate) | |||
| + | Testicular round spermatids, testicular elongated spermatids | SNRPN | M | Methylation sensitive PCR with fragment length analysis | |||||
| + | Arrested spermatogonia Arrested spermatocytes | H19 | P | Bisulphite PCR with single-strand conformation polymorphism (SSCP) analysis | |||||
| Testicular spermatozoa form patients azoospermic due to ANJ, OAZI, CBAVD, HP | H19 MEST | P M | Bisulphite sequencing | + (embryonic developmental arrest in HP patient) | |||||
COBRA = combined bisulphite-PCR restriction analysis, OAT = patients patients presenting with combined oligozoospermia, asthenozoospermia and teratozoospermia, ANJ = Anejaculation, OAZI = secondary inflammatory obstructive azoospermia, CBAVD = obstructive azoospermia due to congenital bilateral absence of the vas deferens, HP = secretory azoospermia due to hypospermatogenesis.
DNA CpG methylation studies of mainly DMRs in human offspring following ART.
| Reference | ART | Control | Sample | DMR | M/P | Results | |
|---|---|---|---|---|---|---|---|
| ICSI + SGA | 19 | Normal weight children after spontaneous conception | Buccal smear | KCNQ1OT1 MEST PEG3 H19 GTL2 PLAGL1 | M M M P P M | 1/19 children had hypermethylation of KCNQ1OT1 and MEST | |
| ICSI | 92 | – | Blood | SNRPN | M | In all 92 children the expected methylation pattern was seen | |
| IVF and ICSI | 18 | Naturally conceived children and BWS patients | Peripheral blood, UCB or placenta | KCNQ1OT1 | M | 3 of 18 IVF children showed hypomethylation at KCNQ1OT1, without BWS phenotype | |
| IVF and ICSI | 112 | Naturally conceived children | UCB, amnion membrane | KCNQ1OT1 H19 SNRPN MEST GRB10 GTL2 GNAS locus | M P M M M PM+P | Only MEST was slightly hypermethylated in IVF compared with ICSI and control samples | |
| IVF | 10 | Naturally conceived children | UCB, placenta | 1536 CpG sites | – | 23% CpG sites differed in UCB and 16% in placenta. Imprinted genes are not extra vulnerable for deregulation. 4/11 tested genes with differential methylation also showed differential expression | |
| IVF and ICSI | 42 | Abortions/stillbirths after spontaneous conception | Chorion villi | H19 MEG3 KCNQ1OT1 MEST NESP55 PEG3 SNRPN NANOG APC | P P M M P M M M+P M+P | IVF villi showed a hypomethylation (3% less) of KCNQ1OT1 | |
| IVF (ICSI unknown) | 45–98 | Naturally conceived children | UCB, cord, placenta | H19 | P | After IVF the intra- and inter-individual variation in methylation is higher. The expression of H19 and IGF2 in placenta and UCB was reduced in the IVF group |
M/P, maternally or paternally methylated; SGA, small for gestational age; UCB, umbilical cord blood.
Figure 6Overview of the results of studies on the effect of ART on methylation and expression of imprinted genes. (A) Overview of mouse data. (B) Overview of human data. A/C = Amnion/Chorion, Bl = Blastocyst, E = embryo with the age, Ex = Expression which indicates either the level of expression or the allelic expression, ET = embryo transfer, GV = germinal vesicle oocyte, M = methylation, MI = oocyte in meiosis I, MII = oocyte in meiosis II, P = placenta with the age, UCB = umbilical cord blood. The numbers refer to the studies: 1. Sato ), 2. Market-Velker ), 3. Fauque ), 4. Fortier ), 5. Rivera ), 6. Doherty ), 7. Mann ), 8. Li ), 9. Market-Velker ), 10. Khosla ), 11. Fauque ), 12. Geuns ), 13. Geuns ), 14. Khoueiry ), 15. El-Maarri ), 16. Borghol ), 17. Geuns ) 18. Chen ), 19. Ibala-Romdhane ), 20. Gomes ), 21. Tierling ), 22. Turan ), 23. Zechner ), 24. Zhang ), 25. Katari ).